SeLux Diagnostics

Cambridge, United States Founded: 2014 • Age: 12 yrs
Developer of alternatives to traditional ELISA assays

About SeLux Diagnostics

SeLux Diagnostics is a company based in Cambridge (United States) founded in 2014.. SeLux Diagnostics has raised $161.01 million across 11 funding rounds from investors including NIH, HHS and RA Capital. SeLux Diagnostics offers products and services including Selux NGP System, Selux Analyzer, and Selux Panels. SeLux Diagnostics operates in a competitive market with competitors including Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others.

  • Headquarter Cambridge, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Selux Diagnostics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $161.01 M (USD)

    in 11 rounds

  • Latest Funding Round
    $48 M (USD), Series C

    Feb 01, 2024

  • Investors
    NIH

    & 6 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SeLux Diagnostics

SeLux Diagnostics offers a comprehensive portfolio of products and services, including Selux NGP System, Selux Analyzer, and Selux Panels. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Provides rapid antibiotic susceptibility testing for infectious diseases.

Offers precise cell health analysis for fast AST results.

Facilitates comprehensive menu for antimicrobial resistance testing.

People of SeLux Diagnostics
Headcount 50-200
Employee Profiles 6
Employee Profiles
People
Adam Steel
Chief Implementation Officer
People
Michele Healy
Chief Financial Officer
People
Jack Percoskie
CFO
People
Kassi Cox Whale, MBA
Director Of Marketing

Unlock access to complete

Funding Insights of SeLux Diagnostics

SeLux Diagnostics has successfully raised a total of $161.01M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 11
  • Last Round Series C — $48.0M
  • First Round

    (01 Apr 2016)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2024 Amount Series C - SeLux Diagnostics Valuation RA Capital Management
Feb, 2022 Amount Series C - SeLux Diagnostics Valuation RA Capital Management
Oct, 2021 Amount Grant - SeLux Diagnostics Valuation

investors

NIH
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SeLux Diagnostics

SeLux Diagnostics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm investing in life sciences & tech sectors
Founded Year Domain Location
Active, long-term growth equity investments are provided globally.
Founded Year Domain Location
Private equity investments are directed across multiple sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SeLux Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SeLux Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Selux Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SeLux Diagnostics

SeLux Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of molecular diagnostic testing solutions
domain founded_year HQ Location
Genome sequencing diagnostics for infectious diseases are developed.
domain founded_year HQ Location
Detection and antibiotic susceptibility testing for blood infections are provided.
domain founded_year HQ Location
Point-of-care systems for screening drug-resistant pathogens are developed.
domain founded_year HQ Location
Develops innovative point-of-care diagnostics using semiconductor-based CMOS biochip technology.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Selux Diagnostics

Frequently Asked Questions about SeLux Diagnostics

When was SeLux Diagnostics founded?

SeLux Diagnostics was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is SeLux Diagnostics located?

SeLux Diagnostics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Is SeLux Diagnostics a funded company?

SeLux Diagnostics is a funded company, having raised a total of $161.01M across 11 funding rounds to date. The company's 1st funding round was a Grant of $2.8M, raised on Apr 01, 2016.

What does SeLux Diagnostics do?

Developer of alternatives to traditional ELISA assays. The company claims that its novel assay replaces the use of enzymes with an alternative that makes it more sensitive and faster than traditional ELISAs. Applications include point-of-care assays that have sensitivity similar to clinical laboratories.

Who are the top competitors of SeLux Diagnostics?

SeLux Diagnostics's top competitors include Cepheid, Day Zero Diagnostics and Specific Technologies.

What products or services does SeLux Diagnostics offer?

SeLux Diagnostics offers Selux NGP System, Selux Analyzer, and Selux Panels.

Who are SeLux Diagnostics's investors?

SeLux Diagnostics has 7 investors. Key investors include NIH, HHS, RA Capital, Northpond Ventures, and Sands Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available